Shire receives FDA approval of Daytrana for ADHD in adolescents

Links shared publicly online about this topic.

1,040
total visits

Shire receives FDA approval of Daytrana for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include

View full resource at news-medical.net

Tags: ADHD, ADHD Medication, Drug, FDA, Concerta, Metadate CD, Metadate ER, Shire

Most Recently Shared on July 7, 2010 at 10:33 am By:

News-Medical.Net

Stroke News: Shire receives FDA approval of Daytrana for ADHD in adolescents: Shire plc, the global specialty bi... http://twurl.nl/n0dct3

2 years ago...

Retweet

Favorite

Also Shared By:

News-Medical.Net

Daytrana gains indication for attention deficit hyperactivity disorder (ADHD) in adolescents - MPR

empr.com — “The FDA has approved Daytrana (methylphenidate transdermal system, from Shire) for the treatment of attention deficit hyperactivity disorder (ADHD) in adolescents 13"17 years of age.” View full resource at empr.com